EIB grants €150 million loan to Alfasigma to accelerate innovation in rare diseases and specialty care

• The EIB financing will support Alfasigma’s R&D investments for the three-year period from 2025 to 2027.
• The funds will help develop and market new medicines in Alfasigma’s main therapeutic areas.

The European Investment Bank (EIB) has signed a €150 million loan agreement with Alfasigma, a global pharmaceutical company founded in Italy, whose products are present in more than 100 markets worldwide.

https://www.eib.org/en/press/all/2025-276-eib-grants-eur150-million-loan-to-alfasigma-to-accelerate-innovation-in-rare-diseases-and-specialty-care